Shana Kay Phares

Keine laufenden Positionen mehr

56 Jahre

Health Technology

Consumer Services

Profil

Shana Kay Phares served as the President & Chief Executive Officer at Blanchette Rockefeller Neurosciences Institute from 2010 to 2016.
She then worked as a Director at Neurotrope, Inc. from 2016 to 2020.
Prior to her career in neuroscience, she earned an undergraduate degree from Harvard University and an MBA from West Virginia University.

Ehemalige bekannte Positionen von Shana Kay Phares

Unternehmen	Position	Ende
NEUROTROPE, INC.	Direktor/Vorstandsmitglied	25.02.2020
Blanchette Rockefeller Neurosciences Institute Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV.	Vorstandsvorsitzender	01.01.2016

Sehen Sie sich die Erfahrung von Shana Kay Phares im Detail an

Ausbildung von Shana Kay Phares

West Virginia University	Masters Business Admin
Harvard University	Undergraduate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Shana Kay Phares im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
Blanchette Rockefeller Neurosciences Institute Blanchette Rockefeller Neurosciences Institute BiotechnologyHealth Technology Blanchette Rockefeller Neurosciences Institute provides health care solutions. The company offers to facilitate molecular signaling, which controls the functions that record our conscience experience. The company is headquartered in Morgantown, WV.	Health Technology
Neurotrope, Inc. Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.	Health Technology